一个破碎的心.

Same author

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

Clinical pharmacology and therapeutics·2017

Same author

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Diabetologia·2005

Same author

INVEST substudies: design and patient characteristics.

Clinical cardiology·2001

Same author

Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry.

American heart journal·2001

Same author

Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization.

American journal of physiology. Heart and circulatory physiology·2001

Same author

Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.

Circulation·2001

Same journal

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

Circulation·2026

Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026

Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026

Same journal

A New <i>Circulation</i>, For You.

Circulation·2026

Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026

Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026

相关实验视频

一个破碎的心.

相关概念视频

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

INVEST substudies: design and patient characteristics.

Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry.

Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization.

Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

A Bundle to Frame Guidelines and American Heart Association Statements.

<i>Circulation</i> Editors and Editorial Board.

A New <i>Circulation</i>, For You.

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

相关实验视频

一个破碎的心.

相关概念视频

相关文章

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

INVEST substudies: design and patient characteristics.

Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry.

Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization.

Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

A Bundle to Frame Guidelines and American Heart Association Statements.

<i>Circulation</i> Editors and Editorial Board.

A New <i>Circulation</i>, For You.

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.